Institution
University of Kentucky
Education•Lexington, Kentucky, United States•
About: University of Kentucky is a education organization based out in Lexington, Kentucky, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 43933 authors who have published 92195 publications receiving 3256087 citations. The organization is also known as: UK.
Topics: Population, Poison control, Health care, Gene, Cancer
Papers published on a yearly basis
Papers
More filters
••
University of Wisconsin-Madison1, Harvard University2, Johns Hopkins University3, UnitedHealth Group4, University of California, San Diego5, University of Kentucky6, Emory University7, Wayne State University8, University at Buffalo9, University of Colorado Denver10, Yale University11, Oregon Health & Science University12, Duke University13
TL;DR: This guideline provides evidence-based recommendations on managing sinusitis, defined as symptomatic inflammation of the paranasal sinuses, and improves diagnostic accuracy for adult rhinosinusitis to reduce inappropriate antibiotic use, reduce inappropriate use of radiographic imaging, and promote appropriate use of ancillary tests that include nasal endoscopy, computed tomography, and testing for allergy and immune function.
Abstract: Objective
This guideline provides evidence-based recommendations on managing sinusitis, defined as symptomatic inflammation of the paranasal sinuses. Sinusitis affects 1 in 7 adults in the United States, resulting in about 31 million individuals diagnosed each year. Since sinusitis almost always involves the nasal cavity, the term rhinosinusitis is preferred. The guideline target patient is aged 18 years or older with uncomplicated rhinosinusitis, evaluated in any setting in which an adult with rhinosinusitis would be identified, monitored, or managed. This guideline is intended for all clinicians who are likely to diagnose and manage adults with sinusitis.
Purpose
The primary purpose of this guideline is to improve diagnostic accuracy for adult rhinosinusitis, reduce inappropriate antibiotic use, reduce inappropriate use of radiographic imaging, and promote appropriate use of ancillary tests that include nasal endoscopy, computed tomography, and testing for allergy and immune function. In creating this guideline the American Academy of Otolaryngology–Head and Neck Surgery Foundation selected a panel representing the fields of allergy, emergency medicine, family medicine, health insurance, immunology, infectious disease, internal medicine, medical informatics, nursing, otolaryngology–head and neck surgery, pulmonology, and radiology.
Results
The panel made strong recommendations that 1) clinicians should distinguish presumed acute bacterial rhinosinusitis (ABRS) from acute rhinosinusitis caused by viral upper respiratory infections and noninfectious conditions, and a clinician should diagnose ABRS when (a) symptoms or signs of acute rhinosinusitis are present 10 days or more beyond the onset of upper respiratory symptoms, or (b) symptoms or signs of acute rhinosinusitis worsen within 10 days after an initial improvement (double worsening), and 2) the management of ABRS should include an assessment of pain, with analgesic treatment based on the severity of pain.
The panel made a recommendation against radiographic imaging for patients who meet diagnostic criteria for acute rhinosinusitis, unless a complication or alternative diagnosis is suspected.
The panel made recommendations that 1) if a decision is made to treat ABRS with an antibiotic agent, the clinician should prescribe amoxicillin as first-line therapy for most adults, 2) if the patient worsens or fails to improve with the initial management option by 7 days, the clinician should reassess the patient to confirm ABRS, exclude other causes of illness, and detect complications, 3) clinicians should distinguish chronic rhinosinusitis (CRS) and recurrent acute rhinosinusitis from isolated episodes of ABRS and other causes of sinonasal symptoms, 4) clinicians should assess the patient with CRS or recurrent acute rhinosinusitis for factors that modify management, such as allergic rhinitis, cystic fibrosis, immunocompromised state, ciliary dyskinesia, and anatomic variation, 5) the clinician should corroborate a diagnosis and/or investigate for underlying causes of CRS and recurrent acute rhinosinusitis, 6) the clinician should obtain computed tomography of the paranasal sinuses in diagnosing or evaluating a patient with CRS or recurrent acute rhinosinusitis, and 7) clinicians should educate/counsel patients with CRS or recurrent acute rhinosinusitis regarding control measures.
The panel offered as options that 1) clinicians may prescribe symptomatic relief in managing viral rhinosinusitis, 2) clinicians may prescribe symptomatic relief in managing ABRS, 3) observation without use of antibiotics is an option for selected adults with uncomplicated ABRS who have mild illness (mild pain and temperature <38.3°C or 101°F) and assurance of follow-up, 4) the clinician may obtain nasal endoscopy in diagnosing or evaluating a patient with CRS or recurrent acute rhinosinusitis, and 5) the clinician may obtain testing for allergy and immune function in evaluating a patient with CRS or recurrent acute rhinosinusitis.
Disclaimer
This clinical practice guideline is not intended as a sole source of guidance for managing adults with rhinosinusitis. Rather, it is designed to assist clinicians by providing an evidence-based framework for decision-making strategies. It is not intended to replace clinical judgment or establish a protocol for all individuals with this condition, and may not provide the only appropriate approach to diagnosing and managing this problem.
933 citations
••
TL;DR: Transgenic and knockout studies have provided important mechanistic insights into the development of choroidal neovascularization, the principal cause of vision loss in age-related macular degeneration, and this in turn has culminated in preclinical and clinical trials of directed molecular interventions.
932 citations
••
University of California, San Diego1, University of Arizona2, Ghent University3, Université libre de Bruxelles4, University of Erlangen-Nuremberg5, California Institute of Technology6, University of Sheffield7, Spanish National Research Council8, University of Basel9, University of British Columbia10, University of California, San Francisco11, Anschutz Medical Campus12, Karolinska University Hospital13, Pompeu Fabra University14, University of South Australia15, Memorial Sloan Kettering Cancer Center16, National Taiwan University17, Hebrew University of Jerusalem18, University of Texas MD Anderson Cancer Center19, Princeton University20, Northeastern University21, Washington University in St. Louis22, University College London23, Duke University24, Royal Children's Hospital25, Claude Bernard University Lyon 126, PSL Research University27, Université Paris-Saclay28, University of Pennsylvania29, Kyoto University30, University of Toulouse31, Queensland University of Technology32, Massachusetts Institute of Technology33, University of Pittsburgh34, University of Kentucky35, Kumamoto University36
TL;DR: This Consensus Statement is the outcome of a 2-year-long discussion among EMT researchers and aims to both clarify the nomenclature and provide definitions and guidelines for EMT research in future publications to reduce misunderstanding and misinterpretation of research data generated in various experimental models.
Abstract: Epithelial-mesenchymal transition (EMT) encompasses dynamic changes in cellular organization from epithelial to mesenchymal phenotypes, which leads to functional changes in cell migration and invasion. EMT occurs in a diverse range of physiological and pathological conditions and is driven by a conserved set of inducing signals, transcriptional regulators and downstream effectors. With over 5,700 publications indexed by Web of Science in 2019 alone, research on EMT is expanding rapidly. This growing interest warrants the need for a consensus among researchers when referring to and undertaking research on EMT. This Consensus Statement, mediated by 'the EMT International Association' (TEMTIA), is the outcome of a 2-year-long discussion among EMT researchers and aims to both clarify the nomenclature and provide definitions and guidelines for EMT research in future publications. We trust that these guidelines will help to reduce misunderstanding and misinterpretation of research data generated in various experimental models and to promote cross-disciplinary collaboration to identify and address key open questions in this research field. While recognizing the importance of maintaining diversity in experimental approaches and conceptual frameworks, we emphasize that lasting contributions of EMT research to increasing our understanding of developmental processes and combatting cancer and other diseases depend on the adoption of a unified terminology to describe EMT.
931 citations
••
TL;DR: In this article, the authors examined the relation between the composition of financially distressed firms' audit committees and the likelihood of receiving going-concern reports for firms experiencing financial distress during 1994 and found that the greater the percentage of affiliated directors on the audit committee, the lower the probability the auditor will issue a going concern report.
Abstract: This study examines the relation between the composition of financially distressed firms' audit committees and the likelihood of receiving going‐concern reports For firms experiencing financial distress during 1994, we find that the greater the percentage of affiliated directors on the audit committee, the lower the probability the auditor will issue a going‐concern report These results support regulators' concern about financial‐reporting quality and the recent calls for more independent audit committees
928 citations
••
University of Texas Health Science Center at Houston1, National Institutes of Health2, University of Tennessee Health Science Center3, Rush University Medical Center4, Washington University in St. Louis5, University of California, San Francisco6, University of Minnesota7, University of Kentucky8, University of Alabama at Birmingham9, Veterans Health Administration10, Northwestern University11
TL;DR: Low-dose diuretic-based (chlorthalidone) treatment is effective in preventing major CVD events, cerebral and cardiac, in both non-insulin-treated diabetic and nondiabetic older patients with ISH.
Abstract: Objective. —To assess the effect of low-dose, diuretic-based antihypertensive treatment on major cardiovascular disease (CVD) event rates in older, non-insulintreated diabetic patients with isolated systolic hypertension (ISH), compared with nondiabetic patients. Design. —Double-blind, randomized, placebo-controlled trial: the Systolic Hypertension in the Elderly Program (SHEP). Setting. —Multiple clinical and support centers in the United States. Paticipants. —a total of 4736 men and women aged 60 years and older at baseline with ISH (systolic blood pressure [BP], ≥160 mm Hg; diastolic BP, Intervention. —The active treatment group received a low dose of chlorthalidone (12.5-25.0 mg/d) with a step-up to atenolol (25.0-50.0 mg/d) or reserpine (0.05-0.10 mg/d) if needed. The placebo group received placebo and any active antihypertensive drugs prescribed by patient's private physician for persistently high BP. Main Outcome Measures. —The 5-year rates of major CVD events, nonfatal plus fatal stroke, nonfatal myocardial infarction (MI) and fatal coronary heart disease (CHD), major CHD events, and all-cause mortality. Results. —The SHEP antihypertensive drug regimen lowered BP of both diabetic and nondiabetic patients, with few adverse effects. For both diabetic and nondiabetic patients, all outcome rates were lower for participants randomized to the active treatment group than for those randomized to the placebo group. Thus, 5-year major CVD rate was lower by 34% for active treatment compared with placebo, both for diabetic patients (95% confidence interval [CI], 6%-54%) and nondiabetic patients (95% CI, 21%-45%). Absolute risk reduction with active treatment compared with placebo was twice as great for diabetic vs nondiabetic patients (101/1000 vs 51/1000 randomized participants at the 5-year follow-up), reflecting the higher risk of diabetic patients. Conclusion. —Low-dose diuretic-based (chlorthalidone) treatment is effective in preventing major CVD events, cerebral and cardiac, in both non-insulin-treated diabetic and nondiabetic older patients with ISH.
914 citations
Authors
Showing all 44305 results
Name | H-index | Papers | Citations |
---|---|---|---|
Mark P. Mattson | 200 | 980 | 138033 |
Carlo M. Croce | 198 | 1135 | 189007 |
Charles A. Dinarello | 190 | 1058 | 139668 |
Richard A. Gibbs | 172 | 889 | 249708 |
Gang Chen | 167 | 3372 | 149819 |
David A. Bennett | 167 | 1142 | 109844 |
Carl W. Cotman | 165 | 809 | 105323 |
Rodney S. Ruoff | 164 | 666 | 194902 |
David Tilman | 158 | 340 | 149473 |
David Cella | 156 | 1258 | 106402 |
Richard E. Smalley | 153 | 494 | 111117 |
Deepak L. Bhatt | 149 | 1973 | 114652 |
Kevin Murphy | 146 | 728 | 120475 |
Jian Yang | 142 | 1818 | 111166 |
Thomas J. Smith | 140 | 1775 | 113919 |